Clinical Trial

Combined Use of Machine Learning and Metabolomics to Improve the Diagnosis and Management of Hyperandrogenism

Study acronym: HYPERMETABO
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Hyperandrogenism is a common reason for consultation, the causes of which can range from common conditions (PCOS) to rarer conditions with major genetic implications (NC21OHD). It is characterized by elevated levels of circulating androgens, mainly testosterone. This excess of androgens usually manifests clinically as increased male-pattern hair growth and, less specifically, acne and alopecia. Its prevalence is estimated at between 6 and 12% in women of reproductive age, and its incidence is increasing. It is also responsible for infertility. As a reminder, infertility is a major public health issue and affects more and more couples around the world. The investigators therefore wish to develop innovative tools to improve the diagnosis and management of hyperandrogenism
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-19.
Trial Details
NCT Number NCT07253454
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Conditions Hyperandrogenism
Enrollment 800 participants
Start Date 2026-01
Primary Completion 2040-12 (estimated)
Study Completion 2040-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-04